BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8440603)

  • 1. The use of recombinant human erythropoietin in end stage renal disease.
    Conlon PJ; Walshe JJ; O'Donnell R; O'Donohoe A; Spencer R; Donohoe J; Carmody M
    Ir J Med Sci; 1993 Jan; 162(1):17-9. PubMed ID: 8440603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis.
    Van Damme-Lombaerts R; Broyer M; Businger J; Baldauf C; Stocker H
    Pediatr Nephrol; 1994 Jun; 8(3):338-42. PubMed ID: 7917862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal dialysis.
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Nephrol; 1997 Oct; 11(5):628-30. PubMed ID: 9323294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis].
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Pol; 1995 Dec; 70(12):1023-8. PubMed ID: 8649941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.
    Winearls CG; Oliver DO; Pippard MJ; Reid C; Downing MR; Cotes PM
    Lancet; 1986 Nov; 2(8517):1175-8. PubMed ID: 2877323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration.
    Eisele G; Bailie GR; Clement C; Wong E
    Perit Dial Int; 1992; 12(1):34-6. PubMed ID: 1543777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
    Stevens ME; Summerfield GP; Hall AA; Beck CA; Harding AJ; Cove-Smith JR; Paterson AD
    BMJ; 1992 Feb; 304(6825):474-7. PubMed ID: 1547417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of haemoglobin levels and blood-transfusion requirements in patients on haemodialysis and on chronic ambulatory peritoneal dialysis.
    Naiker IP; Seedat YK
    S Afr Med J; 1985 Nov; 68(11):785-6. PubMed ID: 4071323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anaemia in CAPD patients with recombinant human erythropoietin.
    Ramello A; Malcangi U; Bruno M; Perosa P; Reina E; Rizzuto A; Nasini MG; Carozzi S
    Adv Perit Dial; 1990; 6():308-11. PubMed ID: 1982834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis.
    Stevens JM; Auer J; Strong CA; Hughes RT; Oliver DO; Winearls CG; Cotes PM
    Nephrol Dial Transplant; 1991; 6(7):487-94. PubMed ID: 1922910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of recombinant erythropoietin in thalassemic patients on dialysis.
    Lai KN; Wong KC; Li PK; Lui SF
    Am J Kidney Dis; 1992 Mar; 19(3):239-45. PubMed ID: 1553968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
    House AA; Pham B; Pagé DE
    Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin in children with chronic renal failure on dialytic and non-dialytic therapy.
    Aikhionbare HA; Winterborn MW; Gyde OH
    Int J Pediatr Nephrol; 1987; 8(1):9-14. PubMed ID: 3583560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
    Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.